J Assoc Acad Minor Phys. 1996;7(4):93-8. Unique Identifier : AIDSLINE
Esophageal disease is a common and important cause of morbidity and
mortality in patients with human immunodeficiency virus (HIV) infection.
The etiology of HIV-related esophageal ulceration varies. After all
known etiologies are excluded, a subgroup of patients remains with
esophageal ulceration known as idiopathic esophageal ulceration (IEU).
Establishing a diagnosis of IEU is critical and precludes unnecessary
treatment with antiviral, antifungal, or antibiotic agents. A review of
the current literature indicates that there are no prospective,
placebo-controlled, randomized, double-blind trials on the specific
treatment of IEU. Several preliminary reports suggest that
corticosteroids and thalidomide may be effective. The incidence and
natural history of IEU are incompletely known. It is important to
establish that any potential therapeutic agents employed to treat IEU do
not increase viral replication or provide viral protection. There is a
need for well-designed, placebo-controlled, prospective studies to
assess the risks and benefits of corticosteroids, thalidomide, and other
agents in the treatment of idiopathic esophageal ulceration.
Adrenal Cortex Hormones/THERAPEUTIC USE *Esophageal
Diseases/EPIDEMIOLOGY/ETIOLOGY/THERAPY Female Human HIV
Infections/*COMPLICATIONS Male Prevalence Prognosis Risk Factors
Ulcer/DRUG THERAPY/EPIDEMIOLOGY/*ETIOLOGY JOURNAL ARTICLE REVIEW